|
It seems ...
|
6
|
Resverlogix Corp.
|
Nov 09, 2015 12:43PM
|
|
New compound - ApaBearDownAzone
|
9
|
Resverlogix Corp.
|
Jun 01, 2017 03:10PM
|
|
New docs on SEDAR
|
6
|
Zenith Epigenetics
|
Jan 01, 2016 10:27AM
|
|
New Interim Financials and MD&A docs on SEDAR
|
4
|
Zenith Epigenetics
|
Mar 30, 2016 03:35PM
|
|
New Interim Financials and MD&A docs on SEDAR
|
5
|
Resverlogix Corp.
|
Dec 16, 2015 10:45AM
|
|
New shares issued?
|
5
|
Zenith Epigenetics
|
Aug 07, 2018 08:36AM
|
|
Nice background article on mCRPC
|
5
|
Zenith Epigenetics
|
Oct 02, 2016 08:29PM
|
|
Novartis' canakinumab (Ilaris)
|
4
|
Resverlogix Corp.
|
Mar 13, 2018 01:32PM
|
|
NYAS Symposium on Apr 28
|
6
|
Resverlogix Corp.
|
Apr 18, 2016 08:19PM
|
|
OncLive article mentioning ZEN-3694
|
5
|
Zenith Epigenetics
|
Jun 15, 2018 07:02PM
|
|
Overcoming a newly recognized form of resistance to modern prostate cancer drugs
|
8
|
Zenith Epigenetics
|
Jun 20, 2021 09:39AM
|
|
PAH Plans get a write up in Pulmonary Hypertension News
|
7
|
Resverlogix Corp.
|
May 21, 2019 08:34AM
|
|
Pfizer and Astellas Announce Top-Line Results from Phase 4 PLATO Trial of XTANDI® (enzalutamide)
|
4
|
Zenith Epigenetics
|
Dec 14, 2016 04:34PM
|
|
Pfizer vs J&J - Nonmetastatic prostate cancer
|
1
|
Zenith Epigenetics
|
Feb 06, 2018 09:54AM
|
|
Pfizer's PCSK9 Inhibitor bococizumab - further development being scrapped
|
5
|
Resverlogix Corp.
|
Nov 01, 2016 11:17AM
|
|
Phase III - Where will it take place
|
4
|
Resverlogix Corp.
|
Sep 07, 2015 06:14PM
|
|
Presentation at BIO 2016
|
3
|
Resverlogix Corp.
|
Jun 07, 2016 02:37PM
|
|
Protecting shares from being borrowed by shorts
|
4
|
Resverlogix Corp.
|
May 18, 2018 11:37AM
|
|
Re: ... unfinished business
|
5
|
Zenith Epigenetics
|
Nov 02, 2018 06:00PM
|
|
Re: 2019 Potential Events
|
4
|
Resverlogix Corp.
|
Jun 10, 2019 08:27PM
|
